Pharmacoeconomic review report : indication : for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older. Fluticasone propionate (Aermony Respiclick) (Teva Canada Innovation) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Asthma--Treatment.

Asthma.

Outcome assessment (Medical care).

Physical Description:

1 online resource (14 pages)

Edition:

Final (with redactions).

Place of Publication:

Ottawa (ON) : CADTH, 2019.

Summary:

Fluticasone propionate (Fp) is an inhaled corticosteroid (ICS), available as a multidose dry powder inhaler (MDPI) (Fp MDPI; Aermony RespiClick). It is indicated for the maintenance treatment of steroid-responsive bronchial asthma in patients 12 years of age or older. The submitted price for a 60-dose pack of Fp MDPI is 16.96 for 55 mcg, 30.96 for 113 mcg, and 48.15 for 232 mcg. The dose of Fp MDPI depends on the severity of the disease. At the recommended dose, administration of one inhalation twice daily, Fp MDPI costs between 206 and 586 per patient per year. Fp is available as an individual treatment in several different inhaler formats, including Fp Diskus (Flovent Diskus) and Fp hydrofluoroalkane (HFA) (Flovent HFA), though none of these were reviewed by CDEC.

Contents:

Abbreviations

Executive Summary

Background

Summary of the Economic Analysis Submitted by the Manufacturer

Key Limitations

Issues for Consideration

Results/Conclusions

Cost Comparison Table

Appendix 1. Reviewer Worksheets

References.

Notes:

Includes bibliographical reference.

Description based on publisher supplied metadata and other sources.